Is there any place for oral anti-restenotic treatment in the era of drug eluting stents?

Heart

Volumn 91, Issue 11, 2005, Pages 1377-1379

  Gershlick, Anthony H ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DILTIAZEM; POLYMER; RAPAMYCIN; STEROID;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG ELUTING STENT; DRUG MECHANISM; DRUG TOLERABILITY; EDITORIAL; HEART ASSIST DEVICE; HUMAN; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; SIDE EFFECT; STANDARDIZATION; THROMBOSIS;

ADMINISTRATION, ORAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; DRUG IMPLANTS; HUMANS; STENTS;

EID: 27444439550     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.060954     Document Type: Editorial

References (11)

1. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
2. Rodriguez A, Bernardi V, Navia J, et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with muitiplevessel disease (ERACI II): 30-day ana one-year follow-up results. J Am Coll Cardiol 2001;37:51-8.
3. The SOS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the stent or surgery trial): a randomised controlled trial. Lancet 2002;360:965-70.
4. Schofer J, Schluter M, Gershlick AH, et al for the E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
5. Stone G, Ellis S, Cox D, et al. A polymer based paclitaxel eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
6. Urban P, Gershlick A, Guagliumi G, et al. MACE predictors after implantation of sirolimus-eluting stents: a report form the e-Cypher registry. Am J Cardial 2004;94:68E.
7. Rodriguez AE, Rodriguez Alemparte M, Vigo CF, et al. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Heart 2005;91:1433-7.
8. Hausleiter J, Kastrati A, Mehilli J, et al for the OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the oral sirolimus to inhibit recurrent in-stent stenosis (OSIRIS) trial. Circulation 2004;110:790-5.
9. Waksman R, Ajani AE, Richard AD, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the oral rapamune to inhibit restenosis (ORBIT) study. J Am Coll Cardiol 2004;44:1386-92.
10. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
11. Versaci F, Gaspardone A, Tomai F. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study). J Am Coll Cardiol 2002;40:1935-42.